Applied Microbiology and Biotechnology

, Volume 61, Issue 5–6, pp 385–392 | Cite as

Industrial production of β-lactam antibiotics

  • R. P. Elander


The industrial production of β-lactam antibiotics by fermentation over the past 50 years is one of the outstanding examples of biotechnology. Today, the β-lactam antibiotics, particularly penicillins and cephalosporins, represent the world's major biotechnology products with worldwide dosage form sales of ~US$ 15 billion or ~65% of the total world market for antibiotics. Over the past five decades, major improvements in the productivity of the producer organisms, Penicillium chrysogenum and Acremonium chrysogenum (syn. Cephalosporium acremonium) and improved fermentation technology have culminated in enhanced productivity and substantial cost reduction. Major fermentation producers are now estimated to record harvest titers of 40–50 g/l for penicillin and 20–25 g/l for cephalosporin C. Recovery yields for penicillin G or penicillin V are now >90%. Chemical and enzymatic hydrolysis process technology for 6-aminopenicillanic acid or 7-aminocephalosporanic acid is also highly efficient (~80–90%) with new enzyme technology leading to major cost reductions over the past decade. Europe remains the dominant manufacturing area for both penicillins and cephalosporins. However, due to ever increasing labor, energy and raw material costs, more bulk manufacturing is moving to the Far East, with China, Korea and India becoming major production countries with dosage form filling becoming more dominant in Puerto Rico and in Ireland.


Fermentation Cephalosporin Clavulanic Acid Temocillin Oral Cephalosporin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Albers-Schoenberg G, Arison BH, Hensens OD, Hirshfield J, Hoogsteen K, Kaczka EA, Rhodes RE, Kahan JJ, Kahan FM, Ratcliffe RW, Walton E, Ruswinkle LJ, Morin RB, Christiansen BG (1978) The structure and absolute configuration of thienamycin. J Am Chem Soc 100:6491–6499Google Scholar
  2. Barber M (1996) The penicillins business. Michael Barber and Associates, 18 Croydon Road, Catterham, Surrey, UKGoogle Scholar
  3. Barber M (2000) The cephalosporins business: 2000 and beyond. Michael Barber and Associates, 18 Croydon Road, Catterham, Surrey, UKGoogle Scholar
  4. Basch J, Chiang S-JD (1998) Genetic engineering approach to reduce undesirable products in cephalosporin C fermentation. J Ind Microbiol Biotechnol 20:344–351Google Scholar
  5. Brakhage AA (1998) Molecular regulation of β-lactam biosynthesis in filamentous fungi. Microbiol Mol Biol Rev 62:547–585PubMedGoogle Scholar
  6. Brown AG, Butterworth D, Cole M, Hanscomb G, Hood JD, Reading C, Rolinson CN (1976) Naturally occurring β-lactamase inhibitors without antibacterial activity. J Antibiot 29:668–669PubMedGoogle Scholar
  7. Cantwell CA, Beckman RJ, Dotzlaf JE, Fisher DL, Skatrud PL, Yeh WH, Queener SW (1990) Cloning and expression of a hybrid Streptomyces clavuligerus cefE gene in Penicillium chrysogenum. Curr Genet 17:213–221PubMedGoogle Scholar
  8. Cantwell CA, Beckman R, Whiteman P, Queener SW, Abraham E (1992) Isolation of deacetoxycephalosporin C from fermentation broths of Penicillium chrysogenum transformants: construction of a new biosynthetic pathway. Proc R Soc London B 238:283–289Google Scholar
  9. Chiang SJ, Chang LT, Chen YS, Hou HH, Elander RP (1991) Strain improvement in Penicillium chrysogenum, from classical genetics to genetic engineering. In: Kleinkauf H, von Dohren H (eds) 50 years of penicillin applications: history and trends. Public, Czech Republic, pp 245–257Google Scholar
  10. Chiang S-JD, Basch J (1999) Cephalosporins. In: Flickinger MC, Drew SW (eds) Encyclopedia of bioprocess technology: fermentations, biocatalysis and bioseparations, vol 1. Wiley, New York, pp 560–570Google Scholar
  11. Crawford L, Stepan AM, McAda PC, Rambosek JA, Conder MJ, Vinci VA, Reeves CD (1995) Production of cephalosporin intermediates by feeding adipic acid to recombinant Penicillium chrysogenum strains expressing ring expansion activity. Biotechnology 13:58–62PubMedGoogle Scholar
  12. Demain AL, Elander RP (1999) The β-lactam antibiotics: past, present and future. Antonie van Leeuwenhoek 75:5–19PubMedGoogle Scholar
  13. Demain AL, Martin JF, Elander RP (1998) Penicillin biochemistry and genetics. In: Mateles RI (ed) Penicillin: a paradigm for biotechnology. Candida, Chicago, pp 98–114Google Scholar
  14. Elander RP, Chiang S-J (1991) Genetics and antibiotic process improvement: from classical genetics to genetic engineering. In: Procop A, Bajpai RK, Ho C (eds) Recombinant DNA technology and applications. McGraw-Hill, New York, pp 153–170Google Scholar
  15. Howarth TT, Brown AG, King TJ (1976) Clavulanic acid, a novel β-lactam isolated from Streptomyces clavuligerus: X-ray crystal structure analysis. J Chem Soc Chem Commun 266–267Google Scholar
  16. Kahan JS, Kahan FM, Goegelman R, Currie SA, Jackson M, Stapley EO, Miller TW, Hendlin D, Mochales S, Hernandez S, Woodrull HB, Birnbaum J (1979) Thienamycin, a new beta-lactam antibiotic. 1, discovery, taxonomy, isolation and physical properties. J Antibiot 32:1–12PubMedGoogle Scholar
  17. Lawrence GC, Lilly G (1980) UK Patent 1,571,888Google Scholar
  18. Matsumoto K (1993) Production of 6-APA, 7-ACA and 7-ADCA by immobilized cephalosporin amidase. In: Tanaka A, Tosa T, Kobayashi T (eds) Industrial application of immobilized biocatalysis. Dekker, New York, pp 67–88Google Scholar
  19. Miller TW (1981) Crystalline N-formimidoylthienamycin. US Patent 4,260,543Google Scholar
  20. Morin RB, Jackson BG, Mueller RA, Lavagnino ER, Scanlon WB, Andrews SL (1963) Chemistry of cephalosporin antibiotics. 3. Chemical correlation of penicillin and cephalosporin antibiotics. J Am Chem Soc 85:1896–1897Google Scholar
  21. Nagarajan R (1972) β-Lactam antibiotics from Streptomyces. In: Flynn EH (ed) Cephalosporins and penicillins: chemistry and biology. Academic Press, New York, pp 636–661Google Scholar
  22. Reading E, Cole M (1977) Clavulanic acid: a beta-lactamase inhibitor from Streptomyces clavuligerus. Antimicrob Agents Chemother 11:852–857PubMedGoogle Scholar
  23. Rowlands RT (1991) Industrial strain improvement and the Panlabs penicillin club. In: Kleinkauf H, von Dohren H (eds) 50 years of penicillin applications: history and trends. Public, Czech Republic, pp 258–266Google Scholar
  24. Savidge TA (1984) Enzymatic conversion used in the production of penicillins and cephalosporins. In: Vandamme E (ed) Biotechnology of industrial antibiotics. Dekker, New York, pp 191–224Google Scholar
  25. Skatrud PL, Tietz AJ, Ingolia TD, Cantwell CA, Fisher DC, Chapman JL, Queener SW (1989) Use of recombinant DNA to improve the production of cephalosporin C by Cephalosporium acremonium. Biotechnology 7:477–485Google Scholar
  26. Stapley EO, Jackson M, Hernandez S, Zimmerman SB, Currie SA, Mochalis S, Mahta JM, Woodruff HB, Hendlin D (1972) Cephamycins, a new family of β-lactam antibiotics. 1. Production by actinomycetes, including Streptomyces lactamdurans sp. n. Antimicrob Agents Chemother 2:122–131Google Scholar
  27. Stapley EO, Birnbaum J, Miller AK, Wallick H, Hendlin D, Woodruff HB (1979) Cefoxitin and cephamycins: microbiological studies. Ref Infect Dis 1:73–87Google Scholar
  28. Strohl WR (1999) Secondary metabolites; antibiotics. In: Flickinger MC, Drew SW (eds) Encyclopedia of bioprocess technology: fermentation, biocatalysis and bioseparations, vol 5. Wiley, New York, pp 2348–2365Google Scholar
  29. Sylvester JC, Coghill RD (1954) The penicillin fermentation. In: Underkofler LA, Hickey RJ (eds) Industrial fermentations, vol 2. Chemical Publishing, New York, pp 219–263Google Scholar
  30. Usher JJ, Lewis MA, Hughes DW, Compton BJ (1988) Development of the cephalosporin C fermentation taking into account the instability of cephalosporin C. Biotechnol Lett 10:543–548Google Scholar
  31. Van der Beck CP, Roels JA (1984) Penicillin production: biotechnology at its best. Antonie van Leeuwenhoek 50:625–639PubMedGoogle Scholar
  32. Van Nistelrooij, Krijgsman J, DeVroom E, Oldenhof C (1998) Penicillin update. In: Mateles RI (ed) Penicillin: a paradigm for biotechnology. Candida, Chicago, pp 85–91Google Scholar
  33. Waites MJ, Morgan NL, Rockey JS, Higton G (2001) Industrial microbiology: an introduction. Blackwell, Oxford, UKGoogle Scholar
  34. Weissenberger HWO, van der Hoeven MB (1970) An efficient non-enzymatic conversion of benzylpenicillin to 6-aminopenicillanic acid. Recl Trav Chim Pays-Bas 89:1081–1084Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Biotechnology ConsultantLa JollaUSA

Personalised recommendations